© 2025 Syngene International Limited. All rights reserved
Syngene’s new biologics facility in the US
Our expanded biologics manufacturing facility in Baltimore, Maryland, marks a strategic step forward in meeting the growing needs of our global partners. With 50KL of single-use bioreactor capacity and dedicated monoclonal antibody (mAb) and recombinant protein production lines, the facility enhances our ability to deliver seamless, end-to-end services—from large molecule discovery and development to commercial-scale manufacturing.
This addition reinforces Syngene’s commitment to delivering scalable, high-quality biologics solutions to global markets.
Let's connect to accelerate your biologics
How this helps our customers
Designed to meet the growing demand for biologics in the U.S.
Greater proximity to U.S. clients
Total 50KL SUB capacity across US and India
mAb and recombinant protein manufacturing lines
Upto 4KL single use bioreactors
Dedicated mammalian cell culture
Full QC suite in U.S with viral clearance testing in India
Integrated delivery from multiple global sites
With our multiple biologics development and manufacturing sites, we offer a unified global supply chain ensuring continuity, flexibility, and reliability for clinical and commercial programs.
Why partner with Syngene
Ready to accelerate your mAb development?
Get the full overview of Syngene’s end-to-end CDMO services